{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:02:45Z","timestamp":1787731365290,"version":"build-2784847793"},"reference-count":198,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The need for preparing new strategies for the design of emergency drug therapies against COVID-19 and similar diseases in the future is rather urgent, considering the high rate of morbidity and especially mortality associated with COVID-19, which so far has exceeded 18 million lives. Such strategies could be conceived by targeting the causes and also the serious toxic side effects of the diseases, as well as associated biochemical and physiological pathways. Deferiprone (L1) is an EMA- and FDA-approved drug used worldwide for the treatment of iron overload and also other conditions where there are no effective treatments. The multi-potent effects and high safety record of L1 in iron loaded and non-iron loaded categories of patients suggests that L1 could be developed as a \u201cmagic bullet\u201d drug against COVID-19 and diseases of similar symptomatology. The mode of action of L1 includes antiviral, antimicrobial, antioxidant, anti-hypoxic and anti-ferroptotic effects, iron buffering interactions with transferrin, iron mobilizing effects from ferritin, macrophages and other cells involved in the immune response and hyperinflammation, as well as many other therapeutic interventions. Similarly, several pharmacological and other characteristics of L1, including extensive tissue distribution and low cost of production, increase the prospect of worldwide availability, as well as many other therapeutic approach strategies involving drug combinations, adjuvant therapies and disease prevention.<\/jats:p>","DOI":"10.3390\/ijms23126735","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:48:12Z","timestamp":1655430492000},"page":"6735","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-7340","authenticated-orcid":false,"given":"George J.","family":"Kontoghiorghes","sequence":"first","affiliation":[{"name":"Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"ref_1","unstructured":"(2022, May 14). WHO Coronavirus (COVID-19) Dashboard. Available online: https.\/\/covid19.who.int."},{"key":"ref_2","unstructured":"COVID-19 Excess Mortality Collaborators (2022). Estimating Excess Mortality Due to the COVID-19 Pandemic: A Systematic Analysis of COVID-19-Related Mortality, 2020\u20132021. Lancet, 399, 1513\u20131536."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.52586\/5064","article-title":"The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic","volume":"26","author":"Kontoghiorghes","year":"2021","journal-title":"Front. Biosci."},{"key":"ref_4","unstructured":"(2022, May 24). Burden of Influenza\u2014WHO\/Europe. Available online: https:\/\/www.euro.who.int\u203ainfluenza\u203aseasonal-influenza."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J., Kolnagou, A., Fetta, S., and Kontoghiorghe, C.N. (2021). Conventional and Unconventional Approaches for Innovative Drug Treatments in COVID-19: Looking Outside of Plato\u2019s Cave. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137208"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Won, J.H., and Lee, H. (2020). The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249775"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Samidurai, A., and Das, A. (2020). Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186790"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Janik, E., Niemcewicz, M., Podogrocki, M., Saluk-Bijak, J., and Bijak, M. (2021). Existing Drugs Considered as Promising in COVID-19 Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115434"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Calabrese, C., Garofalo, E., Bruni, A., Vatrella, A., and Pelaia, G. (2021). Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063059"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S2666-5247(21)00069-0","article-title":"COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room","volume":"2","author":"Olliaro","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(21)00448-7","article-title":"Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients","volume":"397","author":"Amit","year":"2021","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","article-title":"Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7","volume":"593","author":"Davies","year":"2021","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1126\/science.371.6524.9","article-title":"Fast-spreading U.K. virus variant raises alarms","volume":"371","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Nadeem, M.S., Zamzami, M.A., Choudhry, H., Murtaza, B.N., Kazmi, I., Ahmad, H., and Shakoori, A.R. (2020). Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19). Pathogens, 9.","DOI":"10.3390\/pathogens9040307"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12929-020-00703-5","article-title":"Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications","volume":"28","author":"Trougakos","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1002\/jmv.27653","article-title":"The impact of the COVID-19 pandemic on the global burden of influenza","volume":"94","author":"Lampejo","year":"2022","journal-title":"J. Med Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cts.12840","article-title":"Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects","volume":"13","author":"Humeniuk","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate Use of Remdesivir for Patients with Severe COVID-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2020047803","DOI":"10.1542\/peds.2020-047803","article-title":"Compassionate Use of Remdesivir in Children With Severe COVID-19","volume":"145","author":"Goldman","year":"2021","journal-title":"Pediatrics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"n2422","DOI":"10.1136\/bmj.n2422","article-title":"COVID-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n2697","DOI":"10.1136\/bmj.n2697","article-title":"COVID-19: UK becomes first country to authorise antiviral molnupiravir","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"COVID-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"615333","DOI":"10.3389\/fmed.2021.615333","article-title":"The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19","volume":"8","author":"Faria","year":"2021","journal-title":"Front. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00125-022-05670-0","article-title":"Incidence of newly diagnosed diabetes after COVID-19","volume":"65","author":"Rathmann","year":"2022","journal-title":"Diabetologia"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Huang, L., Li, X., Gu, X., Zhang, H., Ren, L., Guo, L., Liu, M., Wang, Y., Cui, D., and Wang, Y. (2022). Health outcomes in people 2 years after surviving hospitalisation with COVID-19: A longitudinal cohort study. Lancet Respir. Med.","DOI":"10.1016\/S2213-2600(22)00126-6"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2102951","DOI":"10.1183\/13993003.02951-2021","article-title":"Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: Possible implications for viral mutagenesis","volume":"59","author":"Evangelou","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2468-2667(22)00042-1","article-title":"COVIDMENT Collaboration. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: An observational study","volume":"7","author":"Lovik","year":"2022","journal-title":"Lancet Public Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"778434","DOI":"10.3389\/fmed.2021.778434","article-title":"COVID-19 Post-acute Sequelae Among Adults: 12 Month Mortality Risk","volume":"8","author":"Mainous","year":"2021","journal-title":"Front. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1038\/s41467-021-26513-3","article-title":"Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status","volume":"12","author":"Xie","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbi.2022.04.013","article-title":"Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections","volume":"103","author":"Taquet","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(85)91472-2","article-title":"New orally active iron chelators","volume":"1","author":"Kontoghiorghes","year":"1985","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e2020011","DOI":"10.4084\/mjhid.2020.011","article-title":"The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia","volume":"12","author":"Kontoghiorghes","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5662\/wjm.v4.i3.163","article-title":"World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients","volume":"4","author":"Kontoghiorghe","year":"2014","journal-title":"World J. Method."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1749-6632.1990.tb24321.x","article-title":"Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia","volume":"612","author":"Kontoghiorghes","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2174\/0929867043364685","article-title":"The design and development of deferiprone (L1) and other iron chelators for clinical use: Targeting methods and application prospects","volume":"11","author":"Kontoghiorghes","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_40","first-page":"659","article-title":"Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals","volume":"43","author":"Sheppard","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0955-3886(00)00102-8","article-title":"Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications","volume":"23","author":"Pashalidis","year":"2000","journal-title":"Transfus Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-4274(95)03415-H","article-title":"Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs","volume":"80","author":"Kontoghiorghes","year":"1995","journal-title":"Toxicol. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/03630260600642484","article-title":"Radiation protection by deferiprone in animal models","volume":"30","author":"Fukuda","year":"2006","journal-title":"Hemoglobin"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"L35","DOI":"10.1016\/S0020-1693(00)84710-6","article-title":"Mobilisation of plutonium and iron from transferrin and ferritin by hydroxypyridone chelators","volume":"125","author":"Taylor","year":"1986","journal-title":"Inorg. Chim. Acta."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/clpt.1990.147","article-title":"Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"48","author":"Kontoghiorghes","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1990.tb07887.x","article-title":"Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies","volume":"76","author":"Kontoghiorghes","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_47","first-page":"288","article-title":"The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels","volume":"34","author":"Fassos","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00277-021-04728-0","article-title":"The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease","volume":"101","author":"Fradette","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2741\/s498","article-title":"New targeted therapies and diagnostic methods for iron overload diseases","volume":"10","author":"Kolnagou","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF02662506","article-title":"T2 relaxation time study of iron overload in b-thalassemia","volume":"6","author":"Mavrogeni","year":"1998","journal-title":"Magn. Reson. Mater. Phys. Biol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload","volume":"22","author":"Anderson","year":"2001","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/03630260903213231","article-title":"Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone\/deferoxamine combination protocol","volume":"33","author":"Kolnagou","year":"2009","journal-title":"Hemoglobin"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/jmri.21707","article-title":"Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia major","volume":"29","author":"Papakonstantinou","year":"2009","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/15376516.2012.727198","article-title":"Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: Factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*","volume":"23","author":"Kolnagou","year":"2013","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.15595","article-title":"MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine","volume":"183","author":"Pepe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/03630260903217182","article-title":"A new era in iron chelation therapy: The design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients","volume":"33","author":"Kontoghiorghes","year":"2009","journal-title":"Hemoglobin"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14740330903535845","article-title":"Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases","volume":"9","author":"Kontoghiorghes","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2019.1631284","article-title":"Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology","volume":"28","author":"Kontoghiorghes","year":"2019","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","article-title":"Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial","volume":"82","author":"Agarwal","year":"1992","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(89)90641-7","article-title":"Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial","volume":"2","author":"Hoffbrand","year":"1989","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(87)90545-9","article-title":"1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload","volume":"1","author":"Kontoghiorghes","year":"1987","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/bmj.295.6612.1509","article-title":"Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"295","author":"Kontoghiorghes","year":"1987","journal-title":"Br. Med. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1055\/s-0043-102691","article-title":"Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination","volume":"67","author":"Kolnagou","year":"2017","journal-title":"Drug Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1532\/IJH97.E0637","article-title":"Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine","volume":"86","author":"Aessopos","year":"2007","journal-title":"Int. J. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17474086.2020.1719359","article-title":"How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?","volume":"13","author":"Kontoghiorghes","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0003-9861(86)90305-X","article-title":"Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts","volume":"246","author":"Halliwell","year":"1986","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/10715768609088062","article-title":"In vitro screening of iron chelators using models of free radical damage","volume":"2","author":"Kontoghiorghes","year":"1986","journal-title":"Free Radic. Res. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10715768709088079","article-title":"Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte","volume":"3","author":"Mostert","year":"1987","journal-title":"Free Radic. Res. Commun."},{"key":"ref_70","first-page":"598","article-title":"Free radicals, antioxidants and human disease: Where are we now?","volume":"119","author":"Halliwell","year":"1992","journal-title":"J. Lab. Clin. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200326080-00003","article-title":"Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: Comparison of epidemiological and therapeutic aspects with deferoxamine","volume":"26","author":"Kontoghiorghes","year":"2003","journal-title":"Drug Saf."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.arcmed.2020.06.012","article-title":"Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review","volume":"51","author":"Roshanravan","year":"2020","journal-title":"Arch. Med. Res."},{"key":"ref_73","first-page":"459","article-title":"Some current insights into oxidative stress","volume":"59","year":"2010","journal-title":"Physiol. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11064-014-1508-7","article-title":"Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone","volume":"40","author":"Maher","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/0971-4065.116293","article-title":"Serum catalytic Iron: A novel biomarker for coronary artery disease in patients on maintenance hemodialysis","volume":"23","author":"Rajapurkar","year":"2013","journal-title":"Indian J. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"799499","DOI":"10.3389\/fcell.2021.799499","article-title":"A Novel Insight Into the Fate of Cardiomyocytes in Ischemia-Reperfusion Injury: From Iron Metabolism to Ferroptosis","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23219","article-title":"Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients","volume":"87","author":"Maggio","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-10-12","article-title":"Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction","volume":"10","author":"Tanner","year":"2008","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2006-04-016949","article-title":"Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)","volume":"109","author":"Fabio","year":"2007","journal-title":"Blood"},{"key":"ref_80","first-page":"1","article-title":"Difficult diagnosis of cardiac haemochromatosis: A case report","volume":"4","author":"Glaveckaite","year":"2020","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.taap.2017.11.005","article-title":"Deferiprone inhibits iron overload-induced tissue factor bearing endothelial microparticle generation by inhibition oxidative stress induced mitochondrial injury, and apoptosis","volume":"338","author":"Chan","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"112381","DOI":"10.1016\/j.biopha.2021.112381","article-title":"Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in \u03b2-thalassemia\/hemoglobin E patients","volume":"145","author":"Morales","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H","article-title":"Increased iron in the dentate nucleus of patients with Friedrich\u2019s ataxia","volume":"46","author":"Waldvogel","year":"1999","journal-title":"Ann. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/archneurol.2008.586","article-title":"Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism","volume":"66","author":"Brar","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jmri.21563","article-title":"MRI assessment of basal ganglia iron deposition in Parkinson\u2019s disease","volume":"28","author":"Wallis","year":"2008","journal-title":"J. Magn. Reson. Imaging."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/10715762.2017.1315114","article-title":"In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer\u2019s disease, Parkinson\u2019s disease, and diabetes","volume":"51","author":"Umeno","year":"2017","journal-title":"Free Radic. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"629414","DOI":"10.3389\/fneur.2021.629414","article-title":"Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders","volume":"12","author":"Iankova","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_88","unstructured":"(2022, May 14). Efficacy and Safety of the Iron Chelator Deferiprone in Parkirson\u2019s Disease (FAIR-PARK-I), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00943748."},{"key":"ref_89","unstructured":"(2022, May 14). Conservative Iron Chelation as a Disease-Modifying Strategy in Parkinson\u2019s Disease: A Multicentric, Parallel-Group, Placebo-Controlled, Randomized Clinical Trial of Deferiprone. Available online: https:\/\/cordis.europa.eu\/project\/id\/633190."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e044107","DOI":"10.1002\/alz.044107","article-title":"Deferiprone to delay dementia (the 3D trial). Human\/Human trials: Other","volume":"16","author":"Ayton","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: Biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2011.043018","article-title":"A pilot trial of deferiprone for neurodegeneration with brain iron accumulation","volume":"96","author":"Abbruzzese","year":"2011","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.parkreldis.2014.03.002","article-title":"Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up","volume":"20","author":"Cossu","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/mds.23751","article-title":"Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial","volume":"26","author":"Zorzi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/mds.22002","article-title":"Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation","volume":"23","author":"Forni","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7279","DOI":"10.4081\/ni.2017.7279","article-title":"A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients","volume":"9","author":"Rohani","year":"2018","journal-title":"Neurol. Int."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00702-019-02138-1","article-title":"Conservative iron chelation for neurodegenerative diseases such as Parkinson\u2019s disease and amyotrophic lateral sclerosis","volume":"127","author":"Devos","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease","volume":"7","author":"Ward","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/15376516.2012.730558","article-title":"Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease","volume":"23","author":"Rajapurkar","year":"2013","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2741\/4253","article-title":"Antioxidant targeting by deferiprone in diseases related to oxidative damage","volume":"19","author":"Kontoghiorghe","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_101","first-page":"161","article-title":"Prospects for introducing deferiprone as potent pharmaceutical antioxidant","volume":"1","author":"Kontoghiorghes","year":"2009","journal-title":"Front. Biosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/1357-2725(94)00084-O","article-title":"Reactive oxygen species and iron\u2014A dangerous partnership in inflammation","volume":"27","author":"Morris","year":"1995","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Paganoni, R., Lechel, A., and Vujic Spasic, M. (2021). Iron at the Interface of Hepatocellular Carcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084097"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/jmv.27693","article-title":"New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression","volume":"94","author":"Liu","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/jsre.1997.5180","article-title":"Iron and atherosclerosis: Inhibition by the iron chelator deferiprone (L1)","volume":"73","author":"Matthews","year":"1997","journal-title":"J. Surg. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"569709","DOI":"10.3389\/fcimb.2020.569709","article-title":"What Can Cellular Redox, Iron, and Reactive Oxygen Species Suggest About the Mechanisms and Potential Therapy of COVID-19?","volume":"10","author":"Muhoberac","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","article-title":"Ferroptosis: Mechanisms and links with diseases","volume":"6","author":"Yan","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-030-62026-4_5","article-title":"Emerging Role for Ferroptosis in Infectious Diseases","volume":"1301","author":"Amaral","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Logie, E., Van Puyvelde, B., Cuypers, B., Schepers, A., Berghmans, H., Verdonck, J., Laukens, K., Godderis, L., Dhaenens, M., and Deforce, D. (2021). Ferroptosis Induction in Multiple Myeloma Cells Triggers DNA Methylation and Histone Modification Changes Associated with Cellular Senescence. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212234"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/cr.2016.95","article-title":"Ferroptosis is an autophagic cell death process","volume":"26","author":"Gao","year":"2016","journal-title":"Cell Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41419-019-2064-5","article-title":"ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation","volume":"10","author":"Park","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1080\/15548627.2016.1187366","article-title":"Autophagy promotes ferroptosis by degradation of ferritin","volume":"12","author":"Hou","year":"2016","journal-title":"Autophagy"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Hetzel, M., Ackermann, M., and Lachmann, N. (2021). Beyond \u201cBig Eaters\u201d: The Versatile Role of Alveolar Macrophages in Health and Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073308"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"761793","DOI":"10.3389\/fmolb.2021.761793","article-title":"NCOA4-Mediated Ferritinophagy: A Vicious Culprit in COVID-19 Pathogenesis?","volume":"8","author":"Jia","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/10715760400011692","article-title":"Secretion of ferritin by iron-laden macrophages and influence of lipoproteins","volume":"38","author":"Yuan","year":"2004","journal-title":"Free Radic. Res."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Pereira, G.J.d.S., Le\u00e3o, A.H.F.F., Erustes, A.G., Morais, I.B.d.M., Vrechi, T.A.d.M., Zamarioli, L.d.S., Pereira, C.C.A.S., Marchioro, L.d., Sperandio, L.P., and Lins, I.V.F. (2021). Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084067"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/ehf2.12958","article-title":"Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): Autopsy reveals a ferroptosis signature","volume":"7","author":"Jacobs","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Fratta Pasini, A.M., Stranieri, C., Girelli, D., Busti, F., and Cominacini, L. (2021). Is Ferroptosis a Key Component of the Process Leading to Multiorgan Damage in COVID-19?. Antioxidants, 10.","DOI":"10.3390\/antiox10111677"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41420-020-00369-w","article-title":"SARS-CoV-2 infection: Can ferroptosis be a potential treatment target for multiple organ involvement?","volume":"6","author":"Yang","year":"2020","journal-title":"Cell Death Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1753466620937175","DOI":"10.1177\/1753466620937175","article-title":"C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis","volume":"14","author":"Huang","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13017-020-00323-2","article-title":"Iron metabolism and lymphocyte characterisation during COVID-19 infection in ICU patients: An observational cohort study","volume":"15","author":"Bolondi","year":"2020","journal-title":"World J. Emerg. Sur."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.redox.2017.08.015","article-title":"Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis","volume":"14","author":"Masaldan","year":"2018","journal-title":"Redox Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e23618","DOI":"10.1002\/jcla.23618","article-title":"Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis","volume":"34","author":"Cheng","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_124","first-page":"429","article-title":"Ferritin as a Marker of Severity in COVID-19 Patients: A Fatal Correlation","volume":"8","author":"Dahan","year":"2020","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.053","article-title":"Serum ferritin as an independent risk factor for severity in COVID-19 patients","volume":"81","author":"Lin","year":"2020","journal-title":"J. Infect."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"mfab021","DOI":"10.1093\/mtomcs\/mfab021","article-title":"Chemistry and biology of ferritin","volume":"3","author":"Plays","year":"2021","journal-title":"Metallomics"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/RHU.0b013e31829ce01f","article-title":"Causes and significance of markedly elevated serum ferritin levels in an academic medical center","volume":"19","author":"Moore","year":"2013","journal-title":"J. Clin. Rheumatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1557.e9","DOI":"10.1016\/j.cmi.2020.02.018","article-title":"Elevation of serum ferritin levels for predicting a poor outcome in hospitalized patients with influenza infection","volume":"26","author":"Lalueza","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.2174\/1381612825666190709202804","article-title":"Hyperferritinaemia: An Iron Sword of Autoimmunity","volume":"25","author":"Islam","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5152\/eurjrheumatol.2014.032","article-title":"The correlation between ferritin level and acute phase parameters in rheumatoid arthritis and systemic lupus erythematosus","volume":"1","author":"Seyhan","year":"2014","journal-title":"Eur. J. Rheumatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/bmj.281.6242.715","article-title":"Synovial fluid ferritin in rheumatoid arthritis","volume":"281","author":"Blake","year":"1980","journal-title":"BMJ"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4081\/cp.2020.1271","article-title":"COVID-19: Hemoglobin, iron, and hypoxia beyond inflammation. A narrative review","volume":"10","author":"Cavezzi","year":"2020","journal-title":"Clin. Pract."},{"key":"ref_133","first-page":"527","article-title":"Etiologies of Extreme Hyperferritinemia\u2014Analysis of a Large Database","volume":"160","author":"Kuntzman","year":"2021","journal-title":"Harefuah"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1042\/bj2330299","article-title":"Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators","volume":"233","author":"Kontoghiorghes","year":"1986","journal-title":"Biochem. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/bj2410087","article-title":"Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators","volume":"241","author":"Kontoghiorghes","year":"1987","journal-title":"Biochem. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ajh.2830340106","article-title":"Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages","volume":"34","author":"Brock","year":"1990","journal-title":"Am. J. Hematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0140-6736(89)92011-4","article-title":"Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients","volume":"2","author":"Vreugdenhil","year":"1989","journal-title":"Lancet"},{"key":"ref_138","first-page":"35","article-title":"Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"9","author":"Vreugdenhil","year":"1991","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"111228","DOI":"10.1016\/j.biopha.2021.111228","article-title":"The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators","volume":"136","author":"Habib","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"101890","DOI":"10.1016\/j.pneurobio.2020.101890","article-title":"Ferroptosis and its potential role in the physiopathology of Parkinson\u2019s Disease","volume":"196","author":"Bouchaoui","year":"2021","journal-title":"Prog. Neurobiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1080\/15548627.2021.1911016","article-title":"Ferritinophagy is involved in the zinc oxide nanoparticles-induced ferroptosis of vascular endothelial cells","volume":"17","author":"Qin","year":"2021","journal-title":"Autophagy"},{"key":"ref_142","first-page":"1","article-title":"Managing Severe Hypoxic Respiratory Failure in COVID-19","volume":"11","author":"Smith","year":"2022","journal-title":"Curr. Emerg. Hosp. Med. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ana.26342","article-title":"Prolonged Unconsciousness is Common in COVID-19 and Associated with Hypoxemia","volume":"91","author":"Waldrop","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"758","DOI":"10.14740\/jocmr4383","article-title":"COVID-19 and Possible Pharmacological Preventive Options","volume":"12","author":"Duner","year":"2020","journal-title":"J. Clin. Med. Res."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Evans, C.E. (2022). Hypoxia-Inducible Factor Signaling in Inflammatory Lung Injury and Repair. Cells, 11.","DOI":"10.3390\/cells11020183"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molmed.2018.10.006","article-title":"Inflammation and Hypoxia: HIF and PHD Isoform Selectivity","volume":"25","author":"Watts","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"621054","DOI":"10.3389\/fphar.2020.621054","article-title":"HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons","volume":"11","author":"Poloznikov","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"837249","DOI":"10.3389\/fphar.2022.837249","article-title":"Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Hirota, K. (2021). HIF-\u03b1 Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050468"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J., and Kontoghiorghe, C.N. (2020). Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells, 9.","DOI":"10.3390\/cells9061456"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1021\/acs.jmedchem.7b01686","article-title":"Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases","volume":"61","author":"Joharapurkar","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00467-017-3849-3","article-title":"HIF stabilizers in the management of renal anemia: From bench to bedside to pediatrics","volume":"34","author":"Kular","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1042\/EBC20180053","article-title":"Role of prolyl hydroxylation in the molecular interactions of collagens","volume":"63","author":"Rappu","year":"2019","journal-title":"Essays Biochem."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J., Kolnagou, A., Kontoghiorghe, C.N., Mourouzidis, L., Timoshnikov, V.A., and Polyakov, N.E. (2020). Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications. Medicines, 7.","DOI":"10.3390\/medicines7080045"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrmicro1930","article-title":"Viral infection and iron metabolism","volume":"6","author":"Drakesmith","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_156","first-page":"1","article-title":"SARS-CoV-2 Infects Red Blood Cell Progenitors and Dysregulates Hemoglobin and Iron Metabolism","volume":"18","author":"Traikov","year":"2022","journal-title":"Stem. Cell Rev. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"24301","DOI":"10.1074\/jbc.M010806200","article-title":"Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: Ribonucleotide reductase maturation as a probe of intracellular iron pools","volume":"276","author":"Romeo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40588-020-00140-w","article-title":"Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival","volume":"7","author":"Liu","year":"2020","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_159","first-page":"1947","article-title":"Therapeutic Potential Of Induced Iron Depletion Using Iron Chelators in COVID-19","volume":"29","author":"Salim","year":"2021","journal-title":"Saudi J. Biol Sci."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Bastin, A., Shiri, H., Zanganeh, S., Fooladi, S., Momeni Moghaddam, M.A., Mehrabani, M., and Nematollahi, M.H. (2021). Iron Chelator or Iron Supplement Consumption in COVID-19? The Role of Iron with Severity Infection. Biol Trace Elem Res., 1\u201311.","DOI":"10.1007\/s12011-021-03048-8"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/dna.2016.3611","article-title":"Hypusination of eIF5A as a Target for Antiviral Therapy","volume":"36","author":"Olsen","year":"2017","journal-title":"DNA Cell Biol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"14814","DOI":"10.1073\/pnas.0904553106","article-title":"Human deoxyhypusine hydroxylase, an enzyme involved in regulating cell growth, activates O2 with a nonheme diiron center","volume":"106","author":"Vu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0006-2952(98)00053-7","article-title":"Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: A hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-1)","volume":"55","author":"Andrus","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Hanauske-Abel, H.M., Saxena, D., Palumbo, P.E., Hanauske, A.R., Luchessi, A.D., Cambiaghi, T.D., Hoque, M., Spino, M., D\u2019Alliessi Gandolfi, D., and Heller, D.S. (2013). Drug-induced reactivation of apoptosis abrogates HIV-1 infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074414"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/315223","article-title":"Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin","volume":"181","author":"Georgiou","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-4690-6-90","article-title":"Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A","volume":"6","author":"Hoque","year":"2009","journal-title":"Retrovirology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.bios.2014.11.038","article-title":"Electrochemical impediometric detection of anti-HIV drug taking gold nanorods as a sensing interface","volume":"66","author":"Narang","year":"2015","journal-title":"Biosens. Bioelectron."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.antiviral.2016.09.006","article-title":"Targeting deoxyhypusine hydroxylase activity impairs cap-independent translation initiation driven by the 5\u2019untranslated region of the HIV-1, HTLV-1, and MMTV mRNAs","volume":"134","author":"Angulo","year":"2016","journal-title":"Antiviral. Res."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Saxena, D., Spino, M., Tricta, F., Connelly, J., Cracchiolo, B.M., Hanauske, A.R., D\u2019Alliessi Gandolfi, D., Mathews, M.B., Karn, J., and Holland, B. (2016). Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154842"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Asha, K., Kumar, P., Sanicas, M., Meseko, C.A., Khanna, M., and Kumar, B. (2018). Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010006"},{"key":"ref_172","first-page":"109","article-title":"Broad spectrum antiviral nucleosides-Our best hope for the future","volume":"57","author":"Thames","year":"2021","journal-title":"Annu. Rep. Med. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3201\/eid2607.200445","article-title":"Rhabdomyolysis as Potential Late Complication Associated with COVID-19","volume":"26","author":"Jin","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1021\/tx049660y","article-title":"Desferrioxamine inhibits production of cytotoxic heme to protein cross-linked myoglobin: A mechanism to protect against oxidative stress without iron chelation","volume":"18","author":"Reeder","year":"2005","journal-title":"Chem Res. Toxicol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"151702","DOI":"10.1016\/j.scitotenv.2021.151702","article-title":"Delineating the impact of COVID-19 on antimicrobial resistance: An Indian perspective","volume":"818","author":"Seethalakshmi","year":"2022","journal-title":"Sci Total Environ."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2021.01.025","article-title":"Iron homeostasis and disorders revisited in the sepsis","volume":"165","author":"Liu","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0168-6445(03)00055-X","article-title":"Bacterial iron homeostasis","volume":"27","author":"Andrews","year":"2003","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(15)00474-2","article-title":"Access to effective antimicrobials: A worldwide challenge","volume":"387","author":"Laxminarayan","year":"2016","journal-title":"Lancet"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Sinapidis, D., Kosmas, V., Vittoros, V., Koutelidakis, I.M., Pantazi, A., Stefos, A., Katsaros, K.E., Akinosoglou, K., Bristianou, M., and Toutouzas, K. (2018). Progression into sepsis: An individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3156-z"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/0024-3205(92)90279-X","article-title":"Iron depletion: A defense against intracellular infection and neoplasm","volume":"50","author":"Weinberg","year":"1992","journal-title":"Life Sci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/13543784.2013.787408","article-title":"Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals","volume":"22","author":"Kontoghiorghe","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"101013","DOI":"10.1016\/j.cegh.2022.101013","article-title":"Mucormycosis: A new threat to Coronavirus disease 2019 with special emphasis on India","volume":"15","author":"Ghosh","year":"2022","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s11033-021-07085-3","article-title":"Resolving the equation between mucormycosis and COVID-19 disease","volume":"49","author":"Pasrija","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/cid\/ciab726","article-title":"Coronavirus Disease 2019-Associated Mucormycosis: Risk Factors and Mechanisms of Disease","volume":"74","author":"Narayanan","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11046-021-00594-6","article-title":"How Does Mucorales Benefit from the Dysregulated Iron Homeostasis During SARS-CoV-2 Infection?","volume":"186","author":"Lugito","year":"2021","journal-title":"Mycopathologia"},{"key":"ref_186","first-page":"e20569","article-title":"Hyperferritinemia and the Extent of Mucormycosis in COVID-19 Patients","volume":"13","author":"Bhadania","year":"2021","journal-title":"Cureus"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/myc.13391","article-title":"Serum iron indices in COVID-19-associated mucormycosis: A case-control study","volume":"65","author":"Kumar","year":"2022","journal-title":"Mycoses"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0268-960X(95)90038-1","article-title":"Iron: Mammalian defense systems, mechanisms of disease, and chelation therapy approaches","volume":"9","author":"Kontoghiorghes","year":"1995","journal-title":"Blood Rev."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/03630269.2010.483662","article-title":"The role of iron and chelators on infections in iron overload and non iron loaded conditions: Prospects for the design of new antimicrobial therapies","volume":"34","author":"Kontoghiorghes","year":"2010","journal-title":"Hemoglobin"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0140-6736(83)91136-4","article-title":"Desferrioxamine and systemic yersiniosis","volume":"322","author":"Prpic","year":"1983","journal-title":"Lancet"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0272-6386(12)80606-8","article-title":"Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry","volume":"18","author":"Boelaert","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkl350","article-title":"Deferiprone iron chelation as a novel therapy for experimental mucormycosis","volume":"58","author":"Ibrahim","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1574-6968.1988.tb02490.x","article-title":"The effect of synthetic iron chelators on bacterial growth in human serum","volume":"1","author":"Brock","year":"1988","journal-title":"FEMS Microbiol. Immunol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2165\/00003495-198529040-00002","article-title":"Ciclopirox olamine 1% cream a preliminary review of its antimicrobial activity and therapeutic use","volume":"29","author":"Jue","year":"1985","journal-title":"Drugs"},{"key":"ref_195","first-page":"140","article-title":"Zinc pyrithione: A topical antimicrobial with complex pharmaceutics","volume":"15","author":"Schwartz","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Lehmann, C., Aali, M., Zhou, J., and Holbein, B. (2021). Comparison of Treatment Effects of Different Iron Chelators in Experimental Models of Sepsis. Life, 11.","DOI":"10.3390\/life11010057"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V72.1.358.358","article-title":"Antimalarial properties of orally active iron chelators","volume":"72","author":"Heppner","year":"1988","journal-title":"Blood"},{"key":"ref_198","first-page":"17","article-title":"Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria","volume":"115","author":"Mohanty","year":"2002","journal-title":"Indian J. Med. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/12\/6735\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:33:18Z","timestamp":1760139198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/12\/6735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":198,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ijms23126735"],"URL":"https:\/\/doi.org\/10.3390\/ijms23126735","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]}}}